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ABSTRACT
Introduction: Coronary heart disease, stroke, 
and peripheral vascular disease are the most 
common causes of mortality in patients with 
type 2 diabetes mellitus (T2DM). The aim 
of these studies was to assess the potential 
for pharmacokinetic interaction between 
dapagliflozin, a sodium glucose co-transporter-2 
inhibitor being developed for the treatment 
of T2DM, and four medications commonly 
prescribed in patients with T2DM and 
cardiovascular disease: simvastatin, valsartan, 
warfarin, and digoxin.
Methods: Potential pharmacokinetic interactions 
between 20 mg dapagliflozin, 40 mg simvastatin, 
or 320 mg valsartan were assessed in an open-
label, randomized, five-period, five-treatment, 
unbalanced crossover study in 24 healthy 
subjects. In a second study, the effects of steady-
state dapagliflozin on the pharmacokinetics of 
25 mg warfarin or 0.25 mg digoxin were assessed 
in an open-label, randomized, two-period, 
two-treatment crossover study in 30 healthy 
subjects divided into two cohorts. The potential 
pharmacodynamic interaction between 
dapagliflozin and warfarin was also evaluated. 
Results: All treatments were well tolerated. 
Neither simvastatin nor valsartan had 
any clinically meaningful effect on the 
pharmacokinetics of dapagliflozin. Dapagliflozin 
increased the area under the curve for 
simvastatin, simvastatin acid, and valsartan by 
approximately 19%, 30%, and 6%, respectively, 
and decreased the maximum observed plasma 
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concentration of valsartan by approximately 
6%. These effects were not considered clinically 
meaningful. In addition, dapagliflozin had no 
effect on the pharmacokinetics of either digoxin 
or warfarin. The pharmacodynamics of warfarin 
were also unaffected by dapagliflozin. 
Conc lus i on :  In  the se  s tud i e s  the  
co-administration of dapagliflozin and 
simvastatin, valsartan, warfarin, or digoxin was 
well tolerated without clinically meaningful 
drug-drug interaction. 
K e y w o r d s :  d a p a g l i f l o z i n ;  d i g o x i n ; 
pharmacokinetics;  pharmacodynamics; 
simvastatin; sodium glucose co-transporter-2; 
type 2 diabetes; valsartan; warfarin
INTRODUCTION
The global burden of diabetes is daunting: 
there were an estimated 285 million sufferers 
worldwide in 2010 [1,2], and this number is 
predicted to rise to 438 million by 2030. Type 
2 diabetes mellitus (T2DM) is the predominant 
form, accounting for approximately 90% of all 
cases of diabetes [3]. T2DM occurs primarily 
in economically developing and newly 
industrialized countries, where it has reached 
epidemic proportions, largely as a result of 
urbanization, associated lifestyle changes, and 
consequent obesity [4]. Increasing body mass 
index (BMI) is associated with an increased 
prevalence of T2DM, dyslipidemia, and 
hypertension [5]. The simultaneous achievement 
of glycemic, blood pressure, and low-density 
lipoprotein targets is pivotal to the management 
of T2DM to avoid cardiovascular disease and 
premature death [6]. 
The medical management of hyperglycemia 
in T2DM concentrates not only on the use of 
lifestyle-directed interventions, but also on 
pharmacologic interventions, such as insulin, 
sulfonylureas, and metformin [7]. Recently, the 
search for insulin-independent mechanisms for 
glycemic control in T2DM has resulted in the 
development of a novel approach - inducing 
renal glucose excretion pharmacologically by 
inhibiting the reabsorption of glucose from 
the glomerular filtrate. Under conditions 
of normoglycemia, virtually all glucose in 
the glomerular filtrate is reabsorbed in the 
proximal tubules, mostly via sodium glucose 
co-transporter-2 (SGLT2) [8]. Dapagliflozin is a 
first-in-class oral, selective, reversible inhibitor 
of SGLT2 in development for the treatment 
of T2DM [9]. Studies in healthy and diabetic 
rats have demonstrated that dapagliflozin 
improves glucose homeostasis [10], and dose-
dependent urinary glucose excretion is induced 
by dapagliflozin in humans [11,12]. Clinical 
studies have also demonstrated the efficacy of 
dapagliflozin in the treatment of T2DM [12-17]. 
There is a clear epidemiologic and 
pathophysiologic link between both micro- 
and macro-vascular disease and T2DM [18]. 
Coronary heart disease, stroke, and peripheral 
vascular disease are the most common causes 
of mortality in patients with T2DM [19]. 
Cardiovascular disease, such as atherosclerosis 
or congestive heart failure, is often present in 
patients with T2DM [20,21]. For this reason, 
in addition to the rigorous management of 
hyperglycemia, dyslipidemia, and hypertension, 
T2DM patients with cardiovascular disease may 
require treatment with commonly prescribed 
cardiovascular drugs, such as warfarin and 
digoxin, to prevent future major cardiovascular 
events and improve prognosis. 
Because of the likelihood of any new 
T2DM therapy being co-administered with 
cardiovascular drugs, the two studies reported 
here were conducted to investigate the safety 
profile of co-administration and the potential 
for pharmacokinetic or pharmacodynamic 
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interaction between dapagliflozin and the 
commonly prescribed dyslipidemic drug 
simvastatin or the angiotensin II receptor 
blocker valsartan, used for the treatment 
of hypertension (study 1; clinicaltrials.
gov identifier: NCT00839683) and between 
dapagliflozin and the anticoagulant warfarin 
or the cardiac glycoside digoxin (study 2; 
clinicaltrials.gov identifier: NCT00904176).
In-vitro pharmacologic studies suggest 
that dapagliflozin is primarily metabolized 
via glucuronidation by uridine diphosphate 
glucuronyl transferase (UGT1A9 enzyme). Under 
in-vitro conditions, dapagliflozin was not found 
to be an inhibitor or an inducer of human 
cytochrome (CYP) isozymes and, although 
it proved to be a substrate for P-glycoprotein 
(P-gp), it has not been demonstrated to be a 
significant P-gp inhibitor. Thus, dapagliflozin 
was not anticipated to significantly affect the 
pharmacokinetics of co-administered drugs that 
are CYP or P-gp substrates [22].
Valsartan is minimally metabolized in 
humans, with no involvement of CYP isozymes 
[23]. In addition, there is no evidence to indicate 
that its rapid absorption is affected by P-gp. 
Simvastatin is metabolized predominantly via 
CYP3A4 [24] and, while a variety of simvastatin 
drug-drug interactions have been observed, 
significant interactions that are clinically 
evident remain rare [25]. S-warfarin, the 
enantiomer that is primarily responsible for 
warfarin’s anticoagulant effects, is principally 
metabolized by CYP2C9 [26]. The metabolism of 
digoxin is reported to be minimal and is also not 
dependent on CYP isozymes. Digoxin is excreted 
in urine and bile largely unchanged [27]. The 
gastrointestinal absorption of digoxin, however, 
does appear to be mediated by P-gp [28]. 
Small alterations in the absorption, free 
fraction, or clearance of these cardiovascular 
drugs - and in particular warfarin and digoxin, 
both of which have a narrow therapeutic 
index - could lead to a decrease in therapeutic 
effect, or to potential toxicity. Therefore, 
although pharmacokinetic interactions are 
not predicted on the basis of the routes of 
metabolism, it is important to confirm a lack 
of clinically significant interaction via clinical 
pharmacokinetic studies. In addition, as there 
is evidence for pharmacodynamic interaction 
of some drugs (for example, rosuvastatin [29]) 
with warfarin without concomitant changes 
in pharmacokinetics, pharmacodynamic 
parameters were also evaluated for warfarin 
(plasma prothrombin time) in the presence and 
absence of dapagliflozin. 
MATERIALS AND METHODS
Subjects
For both studies, male and female subjects deemed 
to be healthy on the basis of medical history, 
physical examination, 12-lead electrocardiogram, 
and clinical laboratory evaluations were eligible. 
Other inclusion criteria were age in the range of 
18-45 years and a BMI of 18-32 kg/m2. No woman 
of child-bearing potential who was breast-feeding, 
pregnant, or not using an acceptable method of 
contraception was eligible. Exclusion criteria 
included a urinary tract infection in the 3 months 
preceding screening, a history of recurrent or 
recent vulvovaginal mycotic infections, and 
current smoking. For study 2, subjects with an 
international normalized ratio (INR) value above 
the upper limit of normal on day 11 of period 1 
were excluded from entering period 2 of the 
study.
Study Designs
Protocol, protocol amendments, and informed 
consent were approved by the respective 
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institutional review boards. Both studies were 
carried out in accordance with the Guidelines 
for Good Clinical Practice and adhered to the 
principles of the Declaration of Helsinki and 
the US Food and Drug Administration (FDA) 
Code of Federal Regulations. Written informed 
consent was obtained from all participants 
prior to enrollment. Healthy subjects were 
screened within 21 days (study 1) and 28 days 
(study 2) prior to initial dosing to establish 
eligibility. Eligible subjects were admitted to the 
clinical research facility on day –1 of period 1 
and remained there until discharge on day 20 
(study 1) or day 23 (study 2). 
Study 1 explored whether dapagliflozin 
had any effects on the pharmacokinetics of 
simvastatin or valsartan, and also whether 
simvastatin or valsartan affected the 
pharmacokinetics of dapagliflozin. Study 2 
evaluated the effects of dapagliflozin on the 
pharmacokinetics of warfarin or digoxin, and 
also assessed the effects of dapagliflozin on the 
pharmacodynamics of warfarin. No evaluation 
of dapagliflozin alone was made in study 2, 
and there was no assessment of the effect of 
warfarin or digoxin on the pharmacokinetics of 
dapagliflozin in this study.
Study 1
This was an open-label, randomized, five-
period, five-treatment, unbalanced crossover 
study (Fig. 1a). Twenty-four enrolled subjects 
(23 men and one woman) were randomized to 
one of 12 treatment sequences and received the 
following five single-dose oral treatments: 20 mg 
dapagliflozin alone, 40 mg simvastatin alone, 
20 mg dapagliflozin plus 40 mg simvastatin, 
320 mg valsartan alone, and 20 mg dapagliflozin 
plus 320 mg valsartan. Subjects were required 
to fast for 10 hours before through to 4 hours 
after study drug administration. All study 
medication was administered at time 0 hours 
with water (240 mL). Serial blood samples 
(a total of three 4-mL samples for each time 
point) were collected for up to 72 hours after 
dosing for the pharmacokinetic assessment 
of dapagliflozin; simvastatin; its major active 
metabolite, simvastatin acid; and valsartan. 
Samples destined for dapagliflozin and 
valsartan analysis were collected in di-potassium 
ethylenediaminetetraacetic acid (K2EDTA) tubes, 
and those for simvastatin and simvastatin acid 
analysis were collected in lithium-heparin 
tubes. Plasma was isolated by centrifugation 
and stored at –20°C for dapagliflozin and –70°C 
for valsartan, simvastatin, and simvastatin acid 
until analyzed. 
Study 2
An open-label, randomized, two-period, 
two-treatment crossover study (Fig. 1b) was 
employed to investigate the effect of steady-
state administration of dapagliflozin on the 
pharmacokinetics of the R- and S-enantiomers 
of warfarin (S-warfarin has approximately five 
times the potency of the R-isomer with respect 
to vitamin K antagonism) [30] or digoxin.
A total of 30 subjects (all men) were randomized to 
one of two study treatments: warfarin (cohort 1, 
comprising 14 subjects) and digoxin (cohort 2, 
comprising 16 subjects). Subjects in cohort 1 
were randomized to receive an oral loading dose 
of 20 mg dapagliflozin on day 1 followed by 
oral administration of 10 mg dapagliflozin once 
daily for 7 days (days 2-8), and co-administration 
with a single oral dose of 25 mg warfarin on 
day 2, or a single oral dose of 25 mg warfarin 
on day 2. The loading dose of dapagliflozin was 
selected to ensure that sufficient exposure was 
achieved at the time of dosing with warfarin or 
digoxin (day 2). Since both warfarin and digoxin 
have long elimination half-lives (t½) relative to 
dapagliflozin, repeat daily dosing of dapagliflozin 
on days 2-8 was necessary after co-administration 
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with warfarin or digoxin to maintain sufficient 
exposure to dapagliflozin to allow adequate 
evaluation of a possible interaction between the 
drugs. The subjects in cohort 2 were randomized 
to receive either an oral loading dose of 
20 mg dapagliflozin on day 1 followed by oral 
administration of 10 mg dapagliflozin once daily 
for 7 days (days 2-8), and co-administration of a 
single oral dose of 0.25 mg digoxin on day 2, or 
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Fig. 1. Design of studies to evaluate potential drug interactions of dapagliflozin with simvastatin, valsartan, warfarin, or 
digoxin. (a) Simvastatin or valsartan. Treatment A: 40 mg simvastatin (single dose); treatment B: 20 mg dapagliflozin (single 
dose) + 40 mg simvastatin (single dose); treatment C: 20 mg dapagliflozin (single dose); treatment D: 320 mg valsartan 
(single dose); and treatment E: 20 mg dapagliflozin (single dose) + 320 mg valsartan (single dose). *Pharmacokinetic 
collection for dapagliflozin and valsartan: 72 hours; for simvastatin/simvastatin acid: 48 hours. D=study discharge; 
R=randomization; S=screening; W=≥4-day washout. (b) Warfarin or digoxin. Treatment A: dapagliflozin 20 mg tablet 
loading dose on day 1 followed by dapagliflozin 10 mg tablet daily on days 2-8 and warfarin 25 mg tablet on day 2 only; 
treatment B: warfarin 25 mg tablet on day 2 only; treatment C: dapagliflozin 20 mg tablet loading dose on day 1 followed 
by dapagliflozin 10 mg tablet once daily on days 2-8 and digoxin 0.25 mg tablet on day 2 only; and treatment D: digoxin 
0.25 mg tablet on day 2 only. D=study discharge; E=enrollment; R=randomization; S=screening; W=washout 9 days 
relative to dosing for warfarin or digoxin.
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In both cohorts, subjects underwent a 9-day 
washout period that separated the single dose of 
either warfarin or digoxin. Fasting requirements 
and study drug intake with water were the 
same as for study 1. Serial blood samples were 
collected in K2EDTA tubes for up to 216 hours 
after dosing for pharmacokinetic assessment of 
R-warfarin, S-warfarin, and digoxin. Plasma was 
isolated by centrifugation and stored at –20°C 
for dapagliflozin, R- and S-warfarin, and digoxin 
until analyzed.
Drug Analyses
Plasma concentrations of dapagliflozin; 
simvastatin; the active metabolite of 
simvastatin, simvastatin acid; valsartan; 
R-warfarin; S-warfarin; and digoxin were assayed 
by validated liquid chromatography-tandem 
mass spectrometry methods in analytical runs 
using appropriate calibration curves and quality 
control samples that met pre-established 
acceptance criteria within the known period of 
analyte stability. The assays were conducted in 
compliance with applicable standard operating 
procedures in place at the time of analysis. For 
study 1, all analyses were conducted by Cedra 
Corporation (Austin, TX, USA), and the respective 
between-run and within-run variability (lower 
limit of quantitation [LLOQ]; upper limit of 
quantitation [ULOQ]) of the assay were: for 
dapagliflozin ≤4.4% and ≤7.2% (1-200 ng/mL); 
for simvastatin ≤2.5% and ≤5.8% (0.1-60 ng/mL);
for simvastatin acid ≤3.5% and ≤8.5% 
(0.05-20 ng/mL); and for valsartan ≤3.6% 
and ≤5.1% (10-8000 ng/mL). For study 2 the 
dapagliflozin analysis was conducted at Cedra, 
and the warfarin and digoxin assays were 
conducted at PPD (Richmond, VA, USA). The 
between-run and within-run variability (LLOQ 
– ULOQ) of the assays were: for dapagliflozin 
≤6.3% and ≤3.9% (1-200 ng/mL); for R-warfarin 
≤3.4% and ≤4.7% (5-1000 ng/mL); for S-warfarin 
≤3.0% and ≤5.0% (5-1000 ng/mL); and for 
digoxin ≤8.4% and ≤14.2% (0.1-50 ng/mL).
Pharmacokinetic and Pharmacodynamic 
Evaluation
Pharmacokinetic parameters were derived 
from plasma concentration versus time data 
and comprised maximum observed plasma 
concentration (Cmax), time to maximum 
observed plasma concentration (tmax), t½, and 
area under the plasma concentration versus 
time curve from time 0 to the last quantifiable 
concentration (AUC0-τ). The pharmacokinetic 
parameters were calculated using Kinetica™ 
version 4.4.1 in eToolbox EP version 2.6.1 
(Thermo Electron Corporation, Philadelphia, 
PA, USA).
Sample Collection
Blood samples for the determination of 
dapagliflozin, simvastatin, simvastatin acid, and 
valsartan were taken at 0, 0.5, 1, 1.5, 2, 3, 4, 6, 
8, 12, 16, 24, 36, 48, and 72 hours after dosing. 
For the determination of S- and R-warfarin 
and digoxin, blood samples were collected 
immediately prior to dosing and at 0.5, 1, 1.5, 
2, 6, 12, 24, 48, 72, 96, 120, 144, 168, 192, and 
216 hours after dosing on day 2.
At each collection time point, 4.0 mL blood 
samples were collected. Separate samples 
were collected into labeled K2EDTA tubes for 
dapagliflozin, valsartan, R-warfarin, S-warfarin, 
and digoxin analysis. For the analysis of both 
simvastatin and simvastatin acid, samples were 
collected into labeled lithium-heparin tubes. 
Immediately after collection, each blood sample 
was gently inverted 8-10 times for complete 
mixing with the anticoagulant and placed on 
wet ice. Within 30 minutes of collection, blood 
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samples were centrifuged at 5°C for 10 minutes 
at 1500×g. Within 15 minutes of centrifugation, 
the plasma was transferred into screw-capped 
polypropylene tubes and stored at or below 
–20°C for dapagliflozin, R- and S-warfarin, and 
digoxin analyses and at or below –70°C for 
valsartan, simvastatin, and simvastatin acid.
The pharmacodynamics of warfarin were 
derived by determining the plasma prothrombin 
time for treatments with warfarin and converting 
these to INR [31]. AUC(INR) and maximum 
observed peak INR value (INRmax) were calculated 
based on derived INR versus time data. The 
plasma prothrombin time measurements were 
assayed with a validated method by St. Luke’s 
Hospital (Kansas City, MO, USA).
Statistical Methods for Pharmacokinetic and 
Pharmacodynamic Analyses
The sample sizes for the studies were not based 
on specific statistical power considerations. 
However, for study 1, data from 22 subjects 
would provide at least 90% confidence that 
the estimated ratios of geometric means for 
simvastatin Cmax and AUC0-τ, with or without 
dapagliflozin, would be within 17% and 24% 
of the true population ratios. For cohort 1 of 
study 2, including 12 subjects provides at least 
90% confidence that the estimated ratios of 
geometric means for S-warfarin Cmax and AUC0-τ, 
with or without dapagliflozin, would be within 
10% and 11% of the true population ratios. 
For cohort 2 of study 2, including 14 subjects 
provides at least 90% confidence that the 
estimated ratios of geometric means for digoxin 
Cmax and AUC0-τ, with or without dapagliflozin, 
would be within 12% and 5% of the true 
population ratios. 
To assess the effects of co-administration, 
point estimates and 90% CIs of the ratios of the 
adjusted geometric means for Cmax and AUC0-τ
of dapagliflozin given in combination with 
the cardiovascular drug under investigation 
and as monotherapy were calculated. The 
adjusted geometric means were obtained from 
general linear mixed models after accounting 
for all other effects in the model. Although not 
predefined, a 90% CI with the usual bounds 
0.80-1.25 was considered indicative of no effect.
To assess the effect of dapagliflozin on the 
pharmacodynamics of warfarin, point estimates 
and 90% CIs were calculated for warfarin alone 
and in the presence of dapagliflozin, and ratios 
of geometric means for AUC(INR) and INRmax were 
calculated based on appropriate general linear 
model analyses. 
Safety Profile
Subjects were monitored throughout the study 
for all adverse events, with information recorded 
on intensity and relationship to study drug in 
the opinion of the investigator. Any serious 
adverse event was also recorded. Vital signs 
(body temperature, respiratory rate) and seated 
blood pressure and heart rate, measured after the 
subject had been seated quietly for ≥5 minutes, 
were evaluated at the screening visit and prior 
to dosing on days 1, 2, and 3 of each period for 
study 1, and on days 1, 2, 5, and 8 for periods 1 
and 2 for study 2. Vital signs were also recorded 
on day –1 of periods 2, 3, 4, and 5 for study 1, 
as well as at study discharge for studies 1 and 2. 
In addition, blood pressure was measured at the 
time of pharmacokinetic sample collection.
RESULTS
Subject Demographics
In study 1, 23 subjects were male and one 
was female; 63% were African American, 29% 
were white, and 8% were of other ethnicity.
170 Adv Ther (2012)  29(2):163-177.
The mean age was 32 years (range, 21-43 years) 
and the mean BMI was 26.8 (range, 19.6-31.6). 
Twenty-three subjects completed study 1. One 
subject discontinued the study because of 
agitation; this subject subsequently went on to 
have a serious adverse event.
In study 2, all 30 subjects were male. The 
predominant ethnic group was white (63%), 
with African American (30%) and other ethnic 
groups (7%) accounting for the remainder. The 
mean age was 28 years (range, 19-45 years) and 
the mean BMI was 25 (range, 18.7-31.5). One 




The mean plasma concentration versus time 
profiles for dapagliflozin, with and without 
simvastatin or valsartan, were comparable 
(Fig. 2). No clinically meaningful changes in the 
pharmacokinetic parameters of dapagliflozin 
were observed when it was administered 
with either simvastatin or valsartan (Table 1).
The 90% CIs for dapagliflozin Cmax and AUC0-τ 
were within the usual no-effect interval of
0.8-1.25. No changes that are likely to be clinically 
meaningful in the t½ and tmax of dapagliflozin 
were observed when co-administered with either 
simvastatin or valsartan.
Simvastatin, Simvastatin Acid, and Valsartan
Mean plasma concentration versus time profiles 
for simvastatin, simvastatin acid, and valsartan 
































Fig. 2. Mean plasma concentration versus time profiles 
for dapagliflozin with and without co-administration of 
simvastatin or valsartan.
Table 1. Pharmacokinetic parameters for dapagliflozin with and without simvastatin or valsartan. 
    Ratio of adjusted geometric 
 Treatment  means point estimate (90% CI)
  Dapagliflozin Dapagliflozin 
 Dapagliflozin and simvastatin  and valsartan
  (n=23) (n=24) (n=24) 
Pharmacokinetic parameter A B C B:A C:A
Cmax, ng/mL* 251  245 221 0.98 (0.89-1.08) 0.88 (0.80-0.98)
AUC0-τ, ng·h/mL* 928 906 947 0.98 (0.95-1.01) 1.02 (1.00-1.05)
tmax, h† 0.55 (0.50-2.03) 1.00 (0.50-2.00) 0.99 (0.48-2.00) – –




AUC0-τ=area under the curve from time 0 to the last quantifiable concentration; Cmax=maximum observed plasma 
concentration; tmax=time to Cmax; t½=half-life.
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There was no clinically meaningful change in 
simvastatin Cmax in the presence of dapagliflozin. 
The 90% CI for the simvastatin Cmax ratio fell 
within the usual no-effect range (Table 2). The 
AUC0-τ geometric mean for simvastatin increased 
by approximately 19% in the presence of 
dapagliflozin, and the upper limit of the 90% CI 
for the AUC0-τ ratio was slightly outside the usual 
1.25 no-effect range (1.40). 
Simvastatin acid Cmax was also unaffected by 
co-administration with dapagliflozin, with the 
90% CI for the Cmax ratio falling within the usual 
no-effect range. The simvastatin acid AUC0-τ
geometric mean increased by approximately 30%, 
and the upper limit for the 90% CI of the AUC0-τ
ratio was slightly outside the usual no-effect 
range (1.47). 
The geometric mean for valsartan Cmax 
and AUC0-τ changed by no more than 6%. 
When valsartan was co-administered with 
dapagliflozin, the 90% CI for the valsartan Cmax 
ratio fell slightly outside the lower bound of the 
usual no-effect range (0.76), and the upper limit 
of the 90% CI for the valsartan AUC0-τ ratio was 
slightly extended beyond the usual no-effect 
range (1.30). 
Warfarin and Digoxin
Mean plasma concentration versus time profiles 
for R-warfarin, S-warfarin, and digoxin, with and 
without dapagliflozin, are shown in Fig. 4. 
The geometric means for Cmax and AUC0-τ
for R-warfarin increased by no more than 8% 
when warfarin 25 mg was administered in the 
presence of dapagliflozin 10 mg relative to those 
observed following administration of warfarin 
25 mg alone (Table 3). The 90% CIs for the ratio 
of the geometric means for Cmax and AUC0-τ for 
R-warfarin, with and without dapagliflozin, 
were all within the usual no-effect interval 
(Table 3). The geometric means for Cmax and 
AUC0-τ for S-warfarin increased by 7% or less 
when warfarin 25 mg was administered in the 
presence of dapagliflozin 10 mg relative to those 
observed following administration of warfarin 
25 mg alone. The 90% CIs for the ratio of 
population geometric means for Cmax and AUC0-τ
for S-warfarin, with and without dapagliflozin, 








































































































Fig. 3. Mean plasma concentration versus time profiles for 
(a) simvastatin, (b) its active metabolite, simvastatin acid, 
and (c) valsartan with and without co-administration of 
dapagliflozin.
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The geometric means for Cmax and AUC0-τ for 
digoxin differed by 1% or less when digoxin 
0.25 mg was administered in the presence 
of dapagliflozin relative to those observed 
following administration of digoxin 0.25 mg 
alone. The 90% CIs for the ratios of geometric 
means, with and without dapagliflozin, were 
within the usual no-effect interval for digoxin 
Cmax and AUC0-τ. 
Pharmacodynamics of Warfarin 
The pharmacodynamics of warfarin were 
unaffected by the co-administration of 
dapagliflozin (Fig. 5). The geometric means 
for INRmax and AUC(INR) both increased by 
approximately 1%, when warfarin was 
administered in the presence of dapagliflozin 
relative to those observed following 
administration of warfarin alone (Table 4). The 
90% CI for the ratio of INRmax and AUC(INR) 
between treatments fell within the usual 
no-effect range.
Safety Profile
Each drug and drug combination was well 
tolerated by the healthy subjects in these two 
studies. No serious adverse events, deaths, 
clinically relevant changes in vital signs or 
12-lead electrocardiograms, or changes in 
physical examination findings were related 
to any of the study treatments. One subject 
experienced a serious adverse event that was 
not attributed to study treatment (psychiatric 
hospitalization) 24 days after being withdrawn 
Table 2. Pharmacokinetic parameters for simvastatin, simvastatin acid, and valsartan, with and without dapagliflozin.
  Treatment 
    Ratio of adjusted geometric
Pharmacokinetic parameter Without dapagliflozin With dapagliflozin means point estimate (90% CI)
Simvastatin
 Cmax, ng/mL* 5.14 4.81 0.94 (0.82-1.07)
 AUC0-τ, ng·h/mL* 25.21 29.90 1.19 (1.01-1.40)
 tmax, h† 1.50 (0.48-8.00) 1.99 (1.00-6.03) –
 t½, h‡ 5.59 (3.50) 7.84 (5.01) –
Simvastatin acid
 Cmax, ng/mL* 1.40 1.50 1.08 (0.93-1.25)
 AUC0-τ, ng·h/mL* 16.40 21.27 1.30 (1.15-1.47)
 tmax, h† 6.00 (2.00-12.00)  6.00 (3.00-411.97) –
 t½, h‡ 8.35 (8.00) 12.21 (12.02) –
Valsartan
 Cmax, ng/mL* 5525 5184 0.94 (0.76-1.16)
 AUC0-τ, ng·h/mL*  38,238 40,536 1.06 (0.87-1.30)
 tmax, h† 3.98 (1.00-5.98) 3.50 (0.50-4.23) –




AUC0-τ=area under the curve from time 0 to the last quantifiable concentration; Cmax=maximum observed plasma 
concentration; tmax=time to Cmax; t½=half-life.
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from study 1. No new clinically relevant 
safety signals emerged when drugs were given 
in combination in either study. A total of
34 adverse events were experienced by subjects 
in study 1; of these, 29 were mild and the 
remainder moderate. In study 2, five subjects 
receiving a combination therapy experienced 
an adverse event. All of these events were mild. 
Marked abnormalities in hematology, 
clinical chemistry, and urinalysis parameters 
were reported in 14 subjects in each study. The 
majority of the marked abnormalities were 
related to urine glucose, which is consistent 
with the pharmacologic effects of dapagliflozin. 
Other laboratory marked abnormalities were 
predominantly mild and transient, and the 
majority were resolved by the end of each of the 
studies.
DISCUSSION
Patients with T2DM, and in particular those 
requiring insulin, have an elevated risk for 
cardiovascular disease compared with the 
general population. This is due to an increase 
in the frequency of cardiovascular risk factors, 
such as dyslipidemia, hypertension, and 
abnormalities with blood clotting. It is estimated 
that approximately 70%-97% of patients with 
T2DM have diabetic dyslipidemia [32], 20%-60% 
have hypertension [33], and approximately 
18% have atrial fibrillation [34]. The risk for 
suffering a stroke is approximately doubled for 
patients with T2DM over the general population 
[35]. Thus, patients diagnosed with T2DM 
often require the co-administration of several 
medications to manage not only glycemia, 
but also any associated cardiovascular risk 
factors. Pharmacokinetic or pharmacodynamic 
interactions between these co-administered 
medications may lead to changes in drug 
exposure or safety concerns. 
Dapagliflozin is under development for T2DM 
and improves glycemic parameters in treatment-
naive patients [14], as well as in those requiring 
oral antihyperglycemic drugs [13,14,36] or 
insulin [16]. As many of these patients, in 
particular those requiring insulin, would be 
expected to require cardiovascular drugs, it 
was necessary to establish the potential for 



































































































Fig. 4. Mean plasma concentration versus time profiles for 
(a) S-warfarin, (b) R-warfarin, and (c) digoxin, with and 
without co-administration of dapagliflozin.
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This study evaluated the interaction of dapagliflozin 
with four commonly prescribed drugs, simvastatin, 
valsartan, warfarin, and digoxin.
The pharmacokinetic profile of dapagliflozin, 
as determined in study 1, was consistent with 
profiles seen in previous monotherapy studies 
performed in healthy subjects [22], and 
the co-administration of either simvastatin 
or valsartan had no impact on the Cmax of 
dapagliflozin or on the overall exposure to 
dapagliflozin, as assessed by AUC0-τ. Similarly, 
the co-administration of dapagliflozin did not 
alter the Cmax of simvastatin. The 90% CI was 
within the usual US FDA-defined no-effect 
range of 0.80-1.25 [37], and the geometric 
mean ratio of simvastatin AUC0-τ was within 
the usual no-effect range, while the upper 
limit value was not within the no-effect range 
(1.40). Furthermore, the co-administration of 
dapagliflozin with simvastatin did not alter the 
Cmax of simvastatin acid, although the geometric 
mean ratio of AUC0-τ was increased by 30%. 
Co-administration of dapagliflozin did not 
appear to alter the Cmax or AUC0-τ of valsartan. 
Table 3. Pharmacokinetic parameters for R- and S-warfarin and digoxin, with and without dapagliflozin.
  Treatment  
    Ratio of adjusted geometric
Pharmacokinetic parameter Without dapagliflozin With dapagliflozin means point estimate (90% CI)
R-warfarin
 Cmax, ng/mL* 1438 1520 1.06 (1.00-1.15)
 AUC0-τ, ng·h/mL* 68,006 73,195 1.08 (1.03-1.12)
 tmax, h† 1.00 (0.50-2.00) 1.00 (0.50-2.00) –
 t½, h‡ 50.8 (11.7) 50.3 (6.1) –
S-warfarin
 Cmax, ng/mL* 1530 1575 1.03 (0.99-1.12)
 AUC0-τ, ng·h/mL*  50,326 54,001 1.07 (1.01-1.14)
 tmax, h† 1.00 (0.50-2.00) 1.00 (0.50-2.00) –
 t½, h‡ 49.3 (11.8) 44.9 (6.3)§ –
Digoxin
 Cmax, ng/mL* 0.846 0.838 0.99 (0.84-1.16)
 AUC0-τ, ng·h/mL*  9.479 9.496 1.00 (0.86-1.17)
 tmax, h† 1.00 (0.50-2.00) 1.00 (0.50-2.02) –




AUC0-τ=area under the curve from time 0 to the last quantifiable concentration; Cmax=maximum observed plasma 





















Fig. 5. Mean INR values versus time. INR=international 
normalized ratio.
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While the 90% CI values were not completely 
contained within the usual 0.80-1.25 no-effect 
interval, these changes were less than two-fold 
and would not warrant a dose adjustment of 
either drug based on FDA guidance. The findings 
of study 2 confirmed the expectation that the 
steady-state administration of dapagliflozin 
would be unlikely to have any substantial effect 
on the pharmacokinetics or pharmacodynamics 
of warfarin and the pharmacokinetics of digoxin. 
Limitations of these studies include the 
predominantly-male (study 1) and all-male 
(study 2) populations studied, healthy subjects, 
small population, and single doses. These results 
are preliminary and larger clinical trials of 
longer duration in patients with T2DM would be 
required to support the evidence presented here. 
However, the results are considered applicable to 
patients with T2DM of either sex since marked sex 
differences are not observed for any of the drugs 
studied; the drug-drug interaction assessments 
are within-subject evaluations within the linear 
pharmacokinetic range of each drug; and none 
show time-dependent pharmacokinetics. 
Dapagliflozin was well tolerated by the 
healthy subjects studied here when administered 
alone or in combination with simvastatin, 
valsartan, warfarin, or digoxin. Any adverse 
events were either mild or moderate in intensity. 
Clinical chemistry was closely monitored, and 
any marked abnormalities were generally mild 
in nature and had resolved by the conclusion 
of the studies. No changes in vital signs were 
observed throughout the course of these studies 
when dapagliflozin was co-administered with 
simvastatin, valsartan, warfarin, or digoxin. 
Once-daily oral dapagliflozin has been 
shown to improve glycemic control without any 
increase in daily insulin requirements and also 
led to weight loss in patients with T2DM poorly 
controlled with insulin [16,38]. Patients such as 
these, with an elevated risk for cardiovascular 
disease, may benefit from insulin-independent 
approaches to controlling hyperglycemia, such 
as SGLT2 inhibition.
CONCLUSION
The absence of any pharmacokinetic interaction 
of dapagliflozin with simvastatin, valsartan, 
warfarin, or digoxin indicates that dapagliflozin 
may be safely co-administered with each of 
these cardiovascular drugs (and presumably 
other drugs with similar metabolism pathways). 
The data from the studies reported here, taken in 
combination with those from previous studies in 
which there was no pharmacokinetic interaction 
of dapagliflozin with drugs that had a variety 
of different metabolism pathways [39], may 
indicate a flexibility of use for dapagliflozin in a 
variety of clinical situations.
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